ReviewBMC cardiovascular disorders2026
Safety profile of ticagrelor: an analysis based on literature and database review.
Review in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTicagrelor, a reversible P2Y12 receptor antagonist, is widely used in acute coronary syndromes (ACS) for its superior efficacy over clopidogrel. However, emerging evidence highlights unique adverse effects, including dyspnea, bradyarrhythmias, QT prolongation, and ventricular pauses. Studies on the real-world safety of ticagrelor are limited. This study aimed to explore the adverse drug reactions (ADRs) linked to ticagrelor and assess their clinical features and management strategies.
methodsWe retrieved data on ADRs related to the P2Y12 receptor antagonist inhibitors ticagrelor from the World Health Organization (WHO) adverse event reporting system database (VigiAccess) for the period from December,2010 to August 2025. Additionally, we conducted a retrospective analysis of case reports and case series on ticagrelor-related ADRs published from 2010 to 2025.
resultsA total of 30,437 ADR reports were analyzed from the WHO-VigiAccess database. The most commonly reported ADRs were dyspnea (6,532 cases, 21.5%), chest pain (1,666 cases, 5.5%), and myocardial infarction (1,337 cases, 4.4%). Bradyarrhythmias, including bradycardia (242 cases), sinus arrest (77 cases), and atrioventricular block (77 cases), were frequently reported. From the literature review, 30 cases of ticagrelor-induced bradyarrhythmias were identified, with a median age of 62.4 years (range: 39–82) and a male predominance (73.3%). The median time to onset was 363 h (range: few mins to 10 months). Management strategies included discontinuation of ticagrelor and switching to clopidogrel or prasugrel, with resolution of symptoms in 93.3% of cases.
conclusionThis review synthesizes data from case and case series reports, and pharmacovigilance databases to analyze ticagrelor’s safety profile, focusing on its adenosine-mediated mechanisms and clinical implications. We propose risk stratification strategies and management algorithms to mitigate these risks, emphasizing the need for vigilant monitoring in high-risk populations. Early identification and active symptomatic treatment to reduce the risk of death are key management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.